Tonix Pharmaceuticals Holding Corp shares are trading higher after the company reported the expansion of its TNX-102 SL 5.6 mg program beyond PTSD to include Phase 3 development for TNX-102 SL in fibromyalgia.
Benzinga Newsdesk